Bispecific Antibodies in the Management of Multiple Myeloma
Dr Joshua Richter from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York, New York, discusses the role of bispecific antibodies in multiple myeloma. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayBispecificMM24).
